---
title: Care
description: Resources and insights tagged care from Pedestal Health.
category: Tag
canonical_url: https://www.pedestalhealth.com/categories/care/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: care
id: 4Btq2RBLjLLnHlxmP0H930
contentType: tag
---

# Care

Resources and insights tagged care from Pedestal Health.

- [Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD](/resources/publications/poster-presentation/impact-of-early-endoscopic-remission-after-advanced-therapy/)
- [Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD](/resources/publications/poster-presentation/impact-of-early-endoscopic-remission-after--2026-unknown/)
- [Machine learning–based identification of moderate-to-severe atopic dermatitis in US patients using the TARGET-DERM AD registry](/resources/publications/poster-presentation/machine-learning-based-identification-of-moderate-to-severe/)
- [A comparison of stable vs progressive hidradenitis suppurativa: insights from TARGET-DERM HS](/resources/publications/poster-presentation/a-comparison-of-stable-vs-progressive-hidradenitis/)
- [The impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM](/resources/publications/poster-presentation/the-impact-of-jak-inhibitor-treatment-on-anxiety-and/)
- [Real world characteristics and burden of patients initiating advanced systemic therapy in the TARGET-DERM atopic dermatitis registry](/resources/publications/poster-presentation/real-world-characteristics-and-burden-of-patients/)
- [Characterization of patient perception of odor severity in hidradenitis suppurativa using TARGET-DERM HS](/resources/publications/poster-presentation/characterization-of-patient-perception-of-odor-severity-in/)
- [Healthcare Disparities in Hidradenitis Suppurativa in the US: TARGET-DERM HS](/resources/publications/poster-presentation/healthcare-disparities-in-hidradenitis-suppurativa-in-the/)
- [Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO](https://scholar.google.com/scholar?q=Characterization%20and%20Impact%20of%20Risankizumab%20on%20patients%20with%20Fistulizing%20Crohn%E2%80%99s%20Disease%20in%20the%20Real%20World%3A%20Findings%20from%20TARGET-GASTRO)
- [Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO](https://scholar.google.com/scholar?q=Characterization%20and%20Impact%20of%20Upadacitinib%20on%20patients%20with%20Fistulizing%20Crohn%E2%80%99s%20Disease%20in%20the%20Real%20World%3A%20Findings%20from%20TARGET-GASTRO)
- [Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease](/resources/publications/poster-presentation/changes-in-the-fibrosis-4-fib-4-score-accurately-reflects/)
- [Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort](/resources/publications/poster-presentation/clinical-characteristics-of-patients-with-presumed-masld/)
- [The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH](https://doi.org/10.1111/apt.70278)
- [Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease](https://doi.org/10.14309/ajg.0000000000003595)
- [DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy](https://doi.org/10.1111/jvh.14056)
- [Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry](https://doi.org/10.1089/derm.2024.0191)
- [Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions](/resources/publications/poster-presentation/relationship-between-non-invasive-tests-clinical-outcomes/)
- [Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis](/resources/publications/poster-presentation/type-2-diabetes-and-obesity-are-the-main-metabolic-risk/)
- [Real-World Treatment Patterns Among US Adults with Unresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)](/resources/publications/poster-presentation/real-world-treatment-patterns-among-us-adults-with/)
- [Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry](/resources/publications/poster-presentation/real-world-treatment-patterns-and-outcomes-for/)
- [Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry](/resources/publications/poster-presentation/correlation-between-achieving-salt-20-score-and-clinician/)
- [Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA](/resources/publications/poster-presentation/race-and-ethnicity-sub-groups-of-alopecia-areata-patients/)
- [Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA](/resources/publications/poster-presentation/generic-vs-disease-specific-patient-reported-outcome-pro/)
- [Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality](/resources/publications/oral-presentation/use-of-glucagon-like-peptide-1-receptor-agonists-in/)
- [Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status](/resources/publications/poster-presentation/stability-of-the-nash-check-patient-reported-outcome/)
- [A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease](/resources/publications/poster-presentation/a-prospective-assessment-of-the-impact-of-decompensation-of/)
- [Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort](/resources/publications/poster-presentation/time-to-disease-progression-and-all-cause-mortality-in/)
- [Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality](/resources/publications/poster-presentation/use-of-sodium-glucose-transport-protein-2-inhibitors-and/)
- [Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort](/resources/publications/poster-presentation/characteristics-of-adult-mash-patients-and-factors/)
- [Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort](/resources/publications/poster-presentation/predictors-of-patients-receiving-no-medication-for/)
- [Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups](/resources/publications/poster-presentation/understanding-metabolic-dysfunction-associated/)
- [Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA](/resources/publications/poster-presentation/complication-free-survival-in-a-real-world-cohort-of-pbc/)
- [Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort](https://doi.org/10.1097/HC9.0000000000000546)
- [High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort](https://doi.org/10.14309/ajg.0000000000002796)
- [Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry](https://doi.org/10.1080/09546634.2024.2428729)
- [Use of Advanced Systemic Therapy in Patients with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry](/resources/publications/abstract-manuscript/use-of-advanced-systemic-therapy-in-patients-with-moderate/)
- [Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH](/resources/publications/poster-presentation/relationship-between-liver-biopsy-fibrosis-stage-and/)
- [Factors Predicting Loss of Remission in Crohn's Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD](/resources/publications/abstract-manuscript/factors-predicting-loss-of-remission-in-crohn-s-disease/)
- [Non-invasive tests as a prediction tool to assess MASH resolution score](/resources/publications/poster-presentation/non-invasive-tests-as-a-prediction-tool-to-assess-mash/)
- [Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study](https://doi.org/10.1097/EDE.0000000000001730)
- [A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH](/resources/publications/poster-presentation/a-longitudinal-assessment-of-cardiovascular-risk-for-nash/)
- [Use of tenofovir-based PrEP among pregnant women in South Africa](https://doi.org/10.1097/QAD.0000000000004090)
- [Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting](/resources/publications/poster-presentation/type-2-diabetes-increases-the-risk-of-progression-to/)
- [Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA](/resources/publications/poster-presentation/demographics-and-disease-characteristics-of-patients-with/)
- [Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH](/resources/publications/poster-presentation/real-world-use-of-glucagon-like-peptide-1-receptor-agonists/)
- [Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry (Fall Clinical 2024)](/resources/publications/poster-presentation/persistent-inadequate-disease-control-and-therapeutic/)
- [A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease](/resources/publications/poster-presentation/a-prospective-assessment-of-disease-progression-impact-on/)
- [Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry](/resources/publications/poster-presentation/why-do-optimal-targets-for-itch-and-skin-clearance-matter/)
- [Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry](/resources/publications/poster-presentation/impact-of-therapeutic-inertia-on--2023-rad-conference/)
- [Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA](/resources/publications/oral-presentation/patient-reported-burden-is-associated-with-clinician/)
- [Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS](/resources/publications/poster-presentation/real-world-study-of-hidradenitis-suppurativa-skin-lesions/)
- [Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States](/resources/publications/poster-presentation/time-to-diagnosis-among-patients-with-eosinophilic/)
- [Assessing The Value Of Linking Abstracted Medical Record Data With Administrative Claims Data To Study Patients With High-Risk Non-Muscle Invasive Bladder Cancer In The United States](/resources/publications/poster-presentation/assessing-the-value-of-linking-abstracted-medical-record/)
- [Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD](/resources/publications/poster-presentation/treatment-journey-among-patients-with-moderate-ulcerative/)
- [Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort](https://doi.org/10.1016/j.cgh.2023.02.024)
- [Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary](https://scholar.google.com/scholar?q=Impact+of+itch+on+quality+of+life+in+people+with+primary+biliary+cholangitis%3A+a+plain+language+summary)
- [The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: Real-world Insights from TARGET-DERM AD](https://academic.oup.com/bjd/article-abstract/188/Supplement_3/ljad162.041/7202475)
- [Healthcare Disparities in Atopic Dermatitis: Insights from TARGET DERM Registry (2022)](/resources/publications/poster-presentation/healthcare-disparities-in--2022-british-journal-dermatology/)
- [NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US](/resources/publications/poster-presentation/nash-progression-rates-based-on-fibrosis-and-inflammation/)
- [Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort](https://doi.org/10.1016/j.jaad.2023.04.052)
- [Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry (RAD Winter 2023)](/resources/publications/poster-presentation/impact-of-therapeutic-inertia-on-patient-reported-outcomes/)
- [Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry](https://doi.org/10.36849/JDD.7473)
- [Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from TARGET-DERM registry (RAD Winter 2023)](/resources/publications/poster-presentation/persistent-inadequate-disease-control--2023-rad-conference/)
- [Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease](https://doi.org/10.14309/ctg.0000000000000620)
- [Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study](/resources/publications/oral-presentation/non-alcoholic-steatohepatitis-disease-progression-in/)
- [A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS](/resources/publications/poster-presentation/a-prospective-pragmatic-post-authorisation-safety-study-of/)
- [Healthcare Disparities in Atopic Dermatitis: Insights from TARGET DERM Registry (2023)](https://academic.oup.com/bjd/article-abstract/188/Supplement_3/ljad162.042/7202453)
- [Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation](https://doi.org/10.1097/EDE.0000000000001598)
- [Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry](/resources/publications/oral-presentation/use-of-advanced-systemic-therapy-in-adolescent-patients/)
- [When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose](https://doi.org/10.1093/cid/ciac700)
- [Use of Advanced Systemic Therapy in Patients with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry (2022)](/resources/publications/poster-presentation/use-of-advanced--2022-current-medical-research-opinion/)
- [Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women](https://doi.org/10.3389/frph.2023.1263422)
- [High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study](https://doi.org/10.1371/journal.pmed.1004088)
- [Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry](/resources/publications/oral-presentation/unmet-needs-of-adolescents-with-moderate-to-severe-atopic/)
- [Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD](/resources/publications/poster-presentation/outcomes-of-early-vs-delayed-advanced-therapy-among/)
- [Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-fracture Treatment Among Commercially Insured Postmenopausal Women in the United States](/resources/publications/oral-presentation/current-trends-in-the-risk-of-subsequent-fracture-after/)
- [Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models](/resources/publications/poster-presentation/analysis-of-discrimination-and-calibration-of-two/)
- [HIV risk perception and PrEP adherence among South African women planning for pregnancy and participating in STI screening](/resources/publications/oral-presentation/hiv-risk-perception-and-prep-adherence-among-south-african/)
- [Healthcare Disparities in Atopic Dermatitis: Insights from TARGET DERM Registry (2023 abstract)](/resources/publications/abstract-manuscript/healthcare-disparities-in-atopic-dermatitis-insights-from/)
- [The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH](/resources/publications/poster-presentation/the-role-of-disease-severity-and-gender-in-polypharmacy/)
- [Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease](https://doi.org/10.3390/children9030374)
- [Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis](https://doi.org/10.1007/s10620-022-07581-x)
- [Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort](https://doi.org/10.1016/j.jaad.2022.08.065)
- [Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD](https://doi.org/10.1186/s12876-022-02143-x)
- [Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort](/resources/publications/poster-presentation/epidemiology-and-burden-of-atopic--2021-rad-conference/)
- [Postpartum Medicaid enrollment and churn in North Carolina](https://doi.org/10.1016/j.ajogmf.2022.100656)
- [The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD](/resources/publications/poster-presentation/the-impact-of-early-vs-late-biologic-initiation-among-real/)
- [Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD](/resources/publications/poster-presentation/treatment-patterns-among-moderate-to-severe-ulcerative/)
- [Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks](/resources/publications/poster-presentation/longitudinal-alt-trajectories-are-generally-stable-among/)
- [Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis](/resources/publications/poster-presentation/inflammation-on-index-biopsy-predicts-loss-of-remission/)
- [Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19](/resources/publications/poster-presentation/healthcare-utilization-and-charges-associated-with-us/)
- [Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19](/resources/publications/poster-presentation/association-between-clinical-outcomes-and-patient/)
- [HIV Incidence in Botswana Rural Communities With High Antiretroviral Treatment Coverage: Results From the Botswana Combination Prevention Project, 2013-2017](https://doi.org/10.1097/QAI.0000000000003017)
- [The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)](/resources/publications/oral-presentation/the-pervasive-impact-of-pruritus-on-quality-of-life-in/)
- [Health Impact and Cost-Effectiveness of HIV Testing, Linkage, and Early Antiretroviral Treatment in the Botswana Combination Prevention Project](https://doi.org/10.1097/QAI.0000000000002996)
- [Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC (APASL)](/resources/publications/oral-presentation/pruritus-in-primary-biliary-cholangitis-is-under-treated-in/)
- [Histological Inflammation Predicts Loss of Remission Among Crohn's Patients with Endoscopic Remission: A US Cohort Analysis](/resources/publications/poster-presentation/histological-inflammation-predicts-loss-of-remission-among/)
- [Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis](https://doi.org/10.1111/apt.16674)
- [Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study](https://doi.org/10.1016/j.cgh.2021.03.031)
- [Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study](https://doi.org/10.1002/hep4.1689)
- [Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort](https://doi.org/10.1016/j.cgh.2021.01.023)
- [Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study](/resources/publications/poster-presentation/determination-of-optimal-thresholds-for-significant/)
- [Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV](https://doi.org/10.1007/s10620-021-07033-y)
- [Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort (RAD 2021)](/resources/publications/poster-presentation/epidemiology-and-burden-of-atopic-dermatitis-involving-the/)
- [Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease](https://doi.org/10.1097/MCG.0000000000001557)
- [Burden of Disease is Positively Associated with Disease Severity in Atopic Dermatitis](/resources/publications/poster-presentation/burden-of-disease-is-positively-associated-with-disease/)
- [Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort](/resources/publications/poster-presentation/immunomodulators-are-commonly-used-as-concomitant-therapy/)
- [Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice](https://doi.org/10.1007/s12325-021-01727-5)
- [Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort](/resources/publications/poster-presentation/biologic-na-ve-patients-with-crohn-s-disease-are-more/)
- [Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid From 2016 to 2018](https://doi.org/10.1001/jamahealthforum.2021.4283)
- [Lipids testing trends before and after hospitalization for myocardial infarction among adults in the United States, 2008-2019](/resources/publications/oral-presentation/lipids-testing-trends-before-and-after-hospitalization-for/)
- [Factors Associated with Readmission in the US Following Hospitalization with COVID-19](https://doi.org/10.1093/cid/ciab464)
- [Burden of Disease is Positively Associated with Disease Severity in Atopic Dermatitis (2021)](/resources/publications/poster-presentation/burden-of-disease-is-positively--2021-rad-conference/)
- [A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes](/resources/publications/poster-presentation/a-pragmatic-clinical-prognostic-classification-suitable-for/)
- [Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice](/resources/publications/poster-presentation/heterogeneous-documentation-and-poor-concordance-of-nash/)
- [Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study](/resources/publications/poster-presentation/fibrosis-assessed-by-non-invasive-tests-is-similar-to-liver/)
- [The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC](/resources/publications/poster-presentation/the-pervasive-impact-of-pruritus-on-quality-of--2020-aasld/)
- [Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC](/resources/publications/poster-presentation/pruritus-in-primary-biliary-cholangitis-is--2020-aasld/)
- [Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease](https://doi.org/10.1159/000511074)
- [Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases](https://doi.org/10.1016/j.cgh.2020.06.066)
- [Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH](/resources/publications/oral-presentation/weight-loss-and-change-in-alanine-aminotransferase-alt/)
- [Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States](https://doi.org/10.2147/CLEP.S229266)
- [Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus](/resources/publications/oral-presentation/clinical-profile-of-nonalcoholic-fatty-liver-disease-in/)
- [Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines](https://doi.org/10.2147/CLEP.S259757)
- [Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States](https://doi.org/10.1093/cid/ciaa1268)
- [Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH](/resources/publications/poster-presentation/predicting-advanced-fibrosis-using-non-invasive-clinical/)
- [Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD](/resources/publications/poster-presentation/factors-associated-with-biologic-discontinuation-in/)
- [Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD](/resources/publications/oral-presentation/objective-disease-activity-assessment-and--2020-ddw/)
- [Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort](/resources/publications/poster-presentation/medication-use-and-comorbidities-among-elderly-as--2019-acg/)
- [Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study (ECCO)](/resources/publications/poster-presentation/oral-mesalamine-use-in-crohn-s-disease-after-implementation/)
- [Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort](/resources/publications/oral-presentation/incidence-of-achieving-weight-loss-goals-in-usual-clinical/)
- [Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort](/resources/publications/poster-presentation/routinely-available-noninvasive-tests-perform-well-in/)
- [Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH](/resources/publications/poster-presentation/patient-reported-outcomes-among-pediatric-patients-with/)
- [Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH](/resources/publications/poster-presentation/patterns-of-medication-use-among-adult-patients-with/)
- [Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort (ACG)](/resources/publications/poster-presentation/medication-use-and-comorbidities-among-elderly-as-compared/)
- [Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study (AASLD)](/resources/publications/poster-presentation/effectiveness-of-tenofovir-alafenamide-in-patients-with/)
- [Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study (ACG)](/resources/publications/poster-presentation/oral-mesalamine-use-in-crohn-s-disease-after--2019-acg/)
- [Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real-world cohort (DDW 2019)](/resources/publications/poster-presentation/primary-biliary-cholangitis-pbc-autoimmune-hepatitis-aih/)
- [Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort (DDW 2019)](/resources/publications/poster-presentation/change-in-lipids-characteristics-and-response-to/)
- [Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US](/resources/publications/poster-presentation/regional-racial-ethnic-and-socioeconomic-disparities-and/)
- [The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease](/resources/publications/poster-presentation/the-prescribing-patterns-and-use-of-statins-in-patients/)
- [Lipid testing trends in the US before and after the release of the 2013 ACC/AHA cholesterol guidelines](/resources/publications/oral-presentation/lipid-testing--2019-american-heart-association-conference/)
- [Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity](/resources/publications/poster-presentation/opioid-use-in-patients-with-nafld-prevalence-and/)
- [Factors Associated with Readmission Following COVID-19 Hospitalization](/resources/publications/poster-presentation/factors-associated-with-readmission-following-covid-19/)
- [Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD](/resources/publications/poster-presentation/lean-nafld-patients-have-lower-prevalence-of-cardiovascular/)
- [Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC)](/resources/publications/poster-presentation/management-of-hepatocellular-carcinoma-hcc-in-a-real-life/)
- [Characterization of polypharmacy in patients with NAFLD](/resources/publications/poster-presentation/characterization-of-polypharmacy-in-patients-with-nafld/)
- [Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC)](/resources/publications/poster-presentation/patient-reported-indicators-of-health-and-symptoms-in-us/)
- [Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD](/resources/publications/poster-presentation/development-of-a-novel-longitudinal-observational-cohort-of/)
- [Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States](https://doi.org/10.1002/cam4.1869)
- [Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US](https://doi.org/10.2147/CLEP.S175063)
- [Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM)](/resources/publications/poster-presentation/clinical-profile-of-adults-with-nonalcoholic/)
- [Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH](/resources/publications/poster-presentation/nonalcoholic-fatty-liver-disease-in-children-in-the-u-s/)
- [Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)](/resources/publications/poster-presentation/real-world-evidence-showing-high-rates-of-cardiovascular/)
- [Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)](/resources/publications/poster-presentation/primary-biliary-cholangitis-pbc-in-the-u-s-real-world/)
- [Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC (DDW)](/resources/publications/poster-presentation/primary-biliary-cholangitis-pbc-in-the-u-s-clinical/)
- [Real-world patterns of romiplostim treatment in adults with primary immune thrombocytopenia in the United States](/resources/publications/oral-presentation/real-world-patterns-of-romiplostim-treatment-in-adults-with/)
- [Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH](/resources/publications/poster-presentation/sustained-elevation-in-alkaline-phosphatase-is-associated/)
- [Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (HEP DART)](/resources/publications/poster-presentation/nonalcoholic-fatty-liver-disease-in-the-u-s-clinical/)
- [Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States](/resources/publications/oral-presentation/patterns-and-predictors-of-initiation-of-intravenous/)

- [DDG 2025 Research: Presentation by Michael Roden, MD](/resources/news/conference-presentation/ddg-2025-research-presentation-by-michael-roden-md/)
- [Pedestal Health (formerly Target RWE) at EASL 2025: Advancing HCC, MASH & PBC Research](/resources/news/press-release/target-rwe-at-easl-2025-advancing-hcc-mash-pbc-research/)
- [EASL 2025 Research: Presentation by Michael Roden, MD](/resources/news/conference-presentation/easl-2025-research-presentation-by-michael-roden-md/)
- [An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data](/resources/news/press-release/an-overview-of-mash-advancements-in-diagnosis-treatment-and-the-role-of-real-world-data/)
- [Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life](/resources/news/press-release/addressing-the-burden-of-hidradenitis-suppurativa-the-often-hidden-impact-on-quality-of-life/)
- [Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies](/resources/news/press-release/patient-centric-data-capture-fuels-growth-of-target-rwe-longitudinal-real-world-dermatology-studies/)
- [New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLD](/resources/news/press-release/new-patient-reported-outcome-insights-from-target-rwe-nash-check-reveals-stability-over-time-and-worse-scores-among-those-with-decompensated-cirrhosis-of-patients-with-masld/)
- [The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD](/resources/news/press-release/the-liver-meeting-2024-research-cirrhosis-presentation-by-arun-j-sanyal-mbbs-md/)
- [The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD](/resources/news/press-release/the-liver-meeting-2024-research-nash-check-presentation-by-arun-j-sanyal-mbbs-md/)
- [The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR](/resources/news/conference-presentation/the-liver-meeting-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr/)
- [ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR](/resources/news/conference-presentation/acg-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr/)
- [ACG 2024 Research: Presentation by Evan S. Dellon, MD, MPH](/resources/news/conference-presentation/acg-2024-research-presentation-by-evan-s-dellon-md-mph/)
- [Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024](/resources/news/press-release/target-rwe-highlights-glp-1-receptor-agonists-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-at-the-liver-meeting-2024/)
- [ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World Registries](/resources/news/press-release/acg-2024-target-rwe-presents-key-mash-and-egids-data-from-leading-liver-disease-gastroenterology-real-world-registries/)
- [New Target RWE Research Validates Updated Liver Disease Terminology in Children](/resources/news/press-release/new-target-rwe-research-validates-updated-liver-disease-terminology-in-children/)
- [Transforming Healthcare Through Data: Ewa J. Kleczyk on Precision Medicine, Diversity, and AI Challenges](/resources/news/press-release/transforming-healthcare-through-data-ewa-j-kleczyk-on-precision-medicine-diversity-and-ai-challenges/)
- [Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions](/resources/news/press-release/real-world-target-nash-analysis-shows-high-concordance-between-new-masld-definitions-and-prior-target-nash-pragmatic-definitions/)
- [EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD](/resources/news/conference-presentation/easl-2024-research-presentation-by-arun-j-sanyal-mbbs-md/)
- [EASL 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR](/resources/news/conference-presentation/easl-2024-research-presentation-by-a-sidney-barritt-iv-md-mscr/)
- [GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024](/resources/news/conference-presentation/glp-1-use-and-nash-check-patient-reported-outcomes-studies-from-target-rwe-presented-at-easl-2024/)
- [Real-World Evidence Leader in Inflammatory Bowel Disease, Target RWE, Announces Expanded Footprint with TARGET-GASTRO Registry of 30,000+ Patients At Digestive Disease Week](/resources/news/conference-presentation/real-world-evidence-leader-in-inflammatory-bowel-disease-target-rwe-announces-expanded-footprint-with-target-gastro-registry-of-30-000plus-patients-at-digestive-disease-week/)
- [Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024](/resources/news/conference-presentation/patient-reported-outcomes-data-from-longest-running-dermatology-study-target-derm-aa-poster-presented-at-american-academy-of-dermatology-aad-2024/)
- [Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care](/resources/news/press-release/overcoming-scalability-challenges-in-real-world-data-processing-for-transformative-patient-care/)
- [Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?](/resources/news/press-release/real-world-evidence-in-pharmaceutical-drug-development-faster-safer-and-more-relevant/)
- [TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options](/resources/news/press-release/target-nash-offers-unprecedented-glimpse-into-growing-public-health-concerns-with-few-treatment-options/)
- [Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population](/resources/news/press-release/leveraging-real-world-evidence-with-analytics-3-essential-components-to-capture-a-360-degree-view-of-your-patient-population/)
- [Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023](/resources/news/conference-presentation/event-recap-blog-target-nash-analysis-presented-at-ispor-2023-and-target-rwe-leaders-present-at-pmsa-2023/)
- [Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023](/resources/news/conference-presentation/ddw-2023-real-world-evidence-leader-target-rwe-shares-expansion-and-update-on-target-gastro-longitudinal-study-during-digestive-disease-week-2023/)
- [Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH](/resources/news/press-release/validation-of-a-pragmatic-clinical-risk-based-classification-of-nash-new-supporting-real-world-evidence-from-target-nash/)
- [Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases](/resources/news/press-release/longest-running-real-world-dermatology-registry-target-derm-offers-deep-insight-into-complex-diseases/)
- [New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)](/resources/news/press-release/new-approaches-for-developing-real-world-evidence-presented-by-target-rwe-at-the-2022-international-conference-on-pharmacoepidemiology-icpe/)
- [Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022](/resources/news/conference-presentation/target-rwe-new-brand-research-and-advanced-real-world-evidence-analytics-showcased-at-international-conference-on-pharmacoepidemiology-icpe-2022/)
- [Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population](/resources/news/press-release/real-world-data-finds-high-prevalence-of-pruritus-itching-and-fatigue-low-levels-of-treatment-in-primary-biliary-cholangitis-population/)
- [Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022](/resources/news/conference-presentation/ilc2022-nonalcoholic-fatty-liver-disease-nafld-research-from-target-rwes-real-world-study-presented-at-international-liver-congress-2022/)
- [New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline Biopsy](/resources/news/conference-presentation/ddw-2022-new-data-presented-at-ddw-2022-shows-nearly-two-fold-risk-of-loss-of-remission-in-ulcerative-colitis-patients-who-had-histologic-inflammation-on-baseline-biopsy/)
- [Target RWE Primary Biliary Cholangitis (PBC) Encore Data Presented at APASL 2022](/resources/news/conference-presentation/target-rwe-primary-biliary-cholangitis-pbc-encore-data-presented-at-apasl-2022/)
- [Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in Children](/resources/news/press-release/large-real-world-study-uncovers-higher-prevalence-of-non-alcoholic-fatty-liver-disease-markers-liver-biopsy-and-cirrhosis-in-children/)
- [TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation](/resources/news/press-release/target-ibd-study-reveals-nearly-a-third-of-patients-with-inflammatory-bowel-disease-did-not-undergo-objective-assessment-prior-to-biologic-dose-change-discontinuation/)
- [Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference](/resources/news/conference-presentation/target-rwe-dermatology-study-data-shared-at-3rd-annual-rad-conference/)
- [Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting](/resources/news/publication-highlight/peer-reviewed-target-rwe-study-finds-wide-variance-in-nonalcoholic-steatohepatitis-nash-pathology-reporting/)
- [Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021](/resources/news/conference-presentation/target-rwe-inflammatory-bowel-disease-research-presented-at-ueg-week-2021/)
- [Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year's Meeting](/resources/news/conference-presentation/update-from-paris-nash-2021-new-target-rwe-nonalcoholic-steatohepatitis-nash-data-presented-at-this-year-s-meeting/)
- [Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences](/resources/news/press-release/target-rwe-hbv-research-on-antiviral-treatments-characteristics-and-clinical-outcomes-published-in-digestive-diseases-and-sciences/)
- [Liver International Publishes Hepatocellular Carcinoma RWE Review](/resources/news/publication-highlight/liver-international-publishes-hepatocellular-carcinoma-rwe-review/)
- [Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients](/resources/news/press-release/target-rwe-study-shows-significant-differences-in-medication-use-among-older-patients-with-ibd-compared-to-younger-patients/)
- [TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease](/resources/news/press-release/target-nash-study-finds-statins-underutilized-in-patients-with-nafld-and-at-risk-of-heart-disease/)
- [Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission](/resources/news/press-release/target-rwe-covid-19-data-real-world-evidence-analysis-shows-36-of-covid-19-hospitalized-patients-discharged-alive-required-readmission/)
- [Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population](/resources/news/conference-presentation/target-rwe-research-presented-at-ddw-2021-shows-high-rates-of-biologic-combination-therapy-and-previous-biologic-exposure-in-ibd-population/)
- [Crohn's & Colitis 360 Publishes Target RWE Inflammatory Bowel Disease Data](/resources/news/publication-highlight/crohn-s-colitis-360-publishes-target-rwe-inflammatory-bowel-disease-data/)
- [TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy](/resources/news/press-release/target-nash-real-world-study-reveals-two-thirds-of-patients-with-nafld-had-no-record-of-liver-biopsy/)
- [Target RWE Shares Weight Loss Data From Ongoing NASH Study](/resources/news/conference-presentation/target-rwe-shares-weight-loss-data-from-ongoing-nash-study/)
- [Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform](/resources/news/press-release/target-rwe-acquires-novisci-inc-adding-significant-analytical-capabilities-to-leading-real-world-evidence-platform/)
- [TARGET-HCC Initial Manuscript Published in Hepatology Communications](/resources/news/publication-highlight/target-hcc-initial-manuscript-published-in-hepatology-communications/)
- [Target RWE Virtual Posters at Annual AIBD, RAD Conferences](/resources/news/press-release/target-rwe-virtual-posters-at-annual-aibd-rad-conferences/)
- [TARGET-DERM Objectives Published in BMJ Open](/resources/news/press-release/target-derm-objectives-published-in-bmj-open/)
- [Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities](/resources/news/conference-presentation/target-rwe-data-presented-at-aasld-virtual-meeting-provides-important-updates-for-nash-and-pbc-communities/)
- [TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use](/resources/news/publication-highlight/target-nash-opioid-manuscript-press-release/)
- [Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study](/resources/news/publication-highlight/target-nash-lean-manuscript-press-release/)
- [EASL 2020: TARGET-NASH Oral Presentation & Abstract Poster Recap](/resources/news/conference-presentation/target-rwe-easl-2020/)
- [Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data Findings](/resources/news/publication-highlight/covid-19-data-set-manuscript-announcement/)
- [Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings](/resources/news/publication-highlight/novel-real-world-data-findings-from-ongoing-target-ibd-study-published-in-ddw-proceedings/)
- [COVID-19 Response](/resources/news/press-release/covid-19-response/)
- [TARGET-IBD Poster & Oral Presentation at ECCO](/resources/news/press-release/target-ibd-poster-oral-presentation-at-ecco/)
- [TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific Meeting](/resources/news/press-release/target-ibd-research-receives-presidential-poster-award-and-outstanding-presenter-award-at-2019-american-college-of-gastroenterology-annual-scientific-meeting/)
- [Alumna Meg Powell Talks with Young Innovators about Clinical Trials](/resources/news/press-release/alumna-meg-powell-talks-with-young-innovators-about-clinical-trials/)
- [TARGET PharmaSolutions Novel Clinical Data Model Helps Drug Industry](/resources/news/press-release/target-pharmasolutions-novel-clinical-data-model-helps-drug-industry/)
- [Intercept Announces OCALIVA (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual Meeting](/resources/news/conference-presentation/intercept-announces-ocaliva-obeticholic-acid-data-in-pbc-to-be-presented-at-the-2016-aasld-annual-meeting/)